POST Online Media Lite Edition


Sagent Pharmaceuticals announces leadership changes

Staff writer |
Schaumburg, Il., USA - March 27, 2015, Schaumburg, Il., USA - Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that Jeffrey Yordon, chairman and chief executive officer, has informed the board of his decision to retire.

Mr. Yordon will remain a member of the Board.

Frank Kung, a well-regarded industry executive and a member of Sagent's Board since 2006, has been named Chairman.

Mr. Kung has served as a member of Sagent's Board of Directors since May 2006. Mr. Kung is a founding member of Vivo Capital, LLC and has been the managing partner since February 1997.

Prior to that, Mr. Kung held the positions of co-founder, Chairman and Chief Executive Officer of Genelabs Technologies, Inc. and co-founder of Cetus Immune Corporation (later acquired by its parent company, Cetus Corporation).

He has served on the board of directors of the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science and Technology Association, West Coast; and the Asian American Manufacturing Association.

He was also appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board.


What to read next

Sagent Pharmaceuticals names Sean Brynjelsen EVP
Sagent Pharmaceuticals appoints James M. Hussey as president
Sagent appoints Michael Fekete to its board of directors